---
type: meeting_r3
---
# Round 3 — Perspective Debate

GROWTH: My perspective as the GROWTH advocate: We go get the $0.50 now, not after PVT when it’s buried in the run rate and we’ve already left margin on the table for thousands of units.

### Where the $0.50 Comes From
Per the Brain, **04-mfg-supplier-quality** has already identified a second-sourced drop-in flex cable that delivers $0.40–$0.50 BOM reduction with no PCB re-spin, no silicon change, no CPU/GPU impact. It’s a passive, electrically equivalent mechanical component swap. That’s the whole play. One part number change, one supplier qualification.

### Why Now, Not Later
The AMG-100 is our GEN 3 flagship — 42% margin at $329 ASP per the Brain. Every dollar we shave off BOM before we ship PVT units is a dollar that compounds across every unit in the field for the product’s entire lifecycle. Waiting until “post-PVT” means we’re deliberately choosing to ship the first X thousand units at the higher cost, then doing a running change that creates its own supply chain bifurcation and retrofit headache. DVT is exactly when you finalize the BOM before you lock PVT. We do it now or we pay a second time to change it later.

### Protecting No Speed Regression (the hard constraint)
Flex cable swap. Not a SoC change. Not memory. Not storage. Not display. Not firmware. The data path from CPU to the dock/power is purely electrical pass-through. **01-hardware-engineering** confirms “electrically equivalent and mechanically zero-tooling” changes are on the table. No retuning of signal integrity, no timing closure, no new firmware. The “no performance regression” gate is trivial here — there’s literally nothing in the data throughput or latency path that changes.

### The Risk We’re Actually Taking
The only risk is reliability qualification, period. And we accept that risk because it’s manageable and insurable within DVT.

**03-quality-reliability** has already told us what they need: an 85/85 bake, connector-cycle testing, and fleet validation on DVT2/PVT units. That’s a defined qualification gate, not an open-ended research project. We fund that gate now from the $6.8M annual budget, negotiate the NRE with the second-source supplier, and run the qual in parallel with the existing DVT activity so it doesn’t slip the critical path. If — and only if — the cable passes the full qualification per Quality’s spec, we cut it into the PVT BOM. If it fails, we kill it with zero impact to the primary BOM and zero delay to DVT exit.

**02-npi-program-management’s** “schedule risk” concern is valid only if we put the qual on the critical path. We don’t. We run it as a concurrent, non-blocking workstream with its own dedicated resources and a hard gate before PVT lock. This is standard NPI portfolio risk management.

**06-finance’s** condition — “zero dollars currently on the ledger” — is not a stop sign; it’s a requirement to ring-fence the scoping expense. So we immediately define the scoping budget (negligible against the $6.8M total), get a PO for the qual NRE, and align Finance’s volume and bench-test triggers before commitment. That’s exactly what their conditional approval asks for. We do the scoping, build the fact base, and present a fully-funded go/no-go to the exec team at the next review.

### Why This Is the Growth Play
Scaling means capturing every basis point of margin we can compound across volume, especially on a product with 42% gross margin that’s about to be our fleet workhorse for years. A $0.50 cost-down on the AMG-100 is not about the first dollar — it’s about the marginal dollar on unit 10,000, unit 50,000, unit 100,000. That’s reinvestment capacity for market expansion, fleet uptime guarantees, and faster RMA turnaround — all of which directly serve the ICP’s pain points of labor shortage, device downtime, and harsh environment durability (per the Brain’s strategy doc).

Delaying cost-down for “post-PVT comfort” is a defense posture. We’re on the GROWTH side. We take the managed risk, fund the qual, and bank the margin now — before the BOM is frozen and every subsequent unit ships with avoidable cost.

CAUTIOUS: From the Brain and the meeting transcript, here is my perspective as the CAUTIOUS side.

**We should not chase this $0.50 right now. We are in DVT, the budget is not in place, and the risk outweighs the reward.**

### 1. This Project Has No Money
Per **06-finance** in the Brain, **"zero dollars are currently on the ledger for BOM cost-down; any work is unfunded until a PO hits the books."** Our annual budget is $6.8M. None of it is allocated here. The Growth argument calls the scoping cost "negligible" and suggests we just "ring-fence" it. That is not how budgets work. You do not start spending engineering time, test-chamber time, and supplier NRE without a cost center and an approved PO. Doing so is how we lose financial control before the product even ships.

### 2. We Are in DVT — The Critical Path Is Sacred
**02-npi-program-management** is unambiguous: **"A $0.50 cost-down at this phase is a schedule risk, not a savings win."** They did not endorse this. They said a flex cable is the least damaging option *if forced*, which is not a recommendation. Introducing a second-source supplier qualification during DVT consumes resources. If there is a yield problem or a connector qualification failure, we are now discussing a delay to PVT. A delay that risks the launch of a $329 product with 42% margin to save 0.15% of the unit price is a bad trade. We protect the critical path first.

### 3. "Drop-In" Is Not Proven — and "Near-Zero" Risk Is Not Zero
**04-mfg-supplier-quality** says the flex cable saving is achievable **"with near-zero quality risk."** "Near-zero" is not a contractual guarantee. A flex cable is not a simple screw; it has impedance characteristics, bend-radius tolerances, and connector retention forces. **03-quality-reliability** correctly points out we have **zero fleet data on the AMG-100**. We have no baseline failure rate. A subtle new failure mode from a different stiffener or copper grain structure could cause intermittent tablet failures in the field. Our ICP, per the Brain, values **"fleet uptime"** above all else. A single-digit field failure rate driven by this change would destroy any savings in RMA cost and brand damage.

### 4. The Quality Gate Is Expensive, Not Free
The Growth argument frames **03-quality-reliability's** "structured qualification gate" as something we just fund and run in parallel. It is not that simple. The 85/85 bake and connector-cycle testing they demand requires dedicated chamber time, statistical sample sizes, and engineering support. **06-finance** has only conditionally approved a "scoping phase" with **"volume and bench-test triggers before commitment"** for full validation. We do not meet those triggers. We are pre-PVT. There is no volume data. Starting this now is unfunded scope creep during the most fragile phase of the product launch.

### My Counter-Proposal
**Reject the DVT cost-down. Formalize it for post-PVT.**

We document the flex cable opportunity in a cost-down pipeline. We promise the executive team a fully-funded, staffed, and gated qualification plan 90 days after PVT entry, when we have real production yield data and a stable baseline to measure against. That is how we protect the 42% margin, the DVT schedule, and the >99.5% fleet uptime vision from the Brain. We do not gamble the launch for $0.50.

BALANCED: Here’s how I see a workable middle ground, pulling from what both sides brought up and sticking to the Brain data.

### The Core Opportunity Is Real and Narrow

Both Growth and Cautious agree on the facts from **04-mfg-supplier-quality** in the Brain: a second-sourced drop-in flex cable for the AMG-100 can deliver a $0.40 to $0.50 BOM reduction. It’s a passive, electrically equivalent component swap—no PCB re-spin, no silicon change, no firmware update. The “no performance regression” hard constraint is met because this cable doesn’t touch the CPU, GPU, memory, storage, or display, so boot time, UI responsiveness, and payment transaction speed aren’t affected. The opportunity is low-risk in engineering terms and high-confidence in its existence. We shouldn’t throw that away, but we also can’t pretend there’s no cost or schedule trade-off.

### The Problem Is Timing and Funding, Not the $0.50 Itself

The Cautious side is right on two critical points:

1. **There is zero budget allocated for this right now.** **06-finance** explicitly says “zero dollars are currently on the ledger for BOM cost-down; any work is unfunded until a PO hits the books.” We have a $6.8M annual budget, but none of it is earmarked here. We can’t start spending engineering time, test-chamber time, or supplier NRE without a defined cost center and an approved PO.

2. **We are in DVT, and the critical path to PVT is sacred.** **02-npi-program-management** flagged that any cost-down at this phase is a schedule risk. Even a flex cable qualification runs in parallel; it still pulls people and lab resources that could otherwise focus on DVT exit.

The Growth side is also right that delaying this until after PVT means we’re deliberately shipping the first production units at a higher cost and then creating a running change later, which has its own supply chain bifurcation and retrofit headaches. So the answer isn’t “do it now” or “do it later”—it’s “do it the moment we have the data and the money to do it safely, and don’t leave it on the shelf.”

### The Balanced Plan: Fund a Scoping Phase Now, Gate Full Qualification on DVT Exit Data

Here’s the middle-ground sequence:

**Step 1: Immediately authorize a small, ring-fenced scoping phase.**
We ask **06-finance** to set up a modest PO—call it a few tens of thousands against the $6.8M budget—for the explicit purpose of scoping. That buys us:
- Engineering time to release the RFQ package for the alternative flex cable to **04-mfg-supplier-quality**.
- A formal quote for the second-source supplier’s NRE and the cost of the qualification plan (85/85 bake, connector-cycle testing, fleet validation units) as defined by **03-quality-reliability**.
- A detailed schedule and resource-loading document from **02-npi-program-management** showing exactly how this workstream would run in parallel, with a hard gate before PVT BOM lock.

This scoping phase doesn’t commit us to the full qualification. It builds the fact base.

**Step 2: Gate the go/no-go for full qualification on DVT exit criteria.**
The Cautious side correctly notes that **03-quality-reliability** wants “a structured qualification gate” and that we have “zero fleet data on the AMG-100.” So the trigger to actually spend the NRE and run the full qual should be: successful DVT exit with stable yield and a preliminary reliability baseline. That gives us real production data from our own line before we introduce any change. If DVT shows any unexpected quality issues, we don’t add a variable. If DVT exits cleanly, we have a stable platform to measure the flex cable against.

**Step 3: Run the qualification before PVT BOM lock, only if DVT exit is clean.**
If we get a clean DVT exit, we take the scoped plan from Step 1, now fully funded with a PO that Finance has approved, and run the flex cable qualification in a non-blocking workstream. The qualification gates are exactly what **03-quality-reliability** specified: 85/85 environmental stress, connector-cycle testing, and fleet validation on DVT2/PVT units. If the cable passes, it goes into the PVT BOM. If it fails, we kill it with no impact to the primary BOM and no delay to PVT, because the primary cable remains the default. **02-npi-program-management** signs off on the schedule before we start, to ensure it doesn’t slip the critical path.

**Step 4: If DVT exit is delayed or shows quality issues, we defer the cost-down to post-PVT.**
In that scenario, we document the flex cable opportunity in a formal cost-down pipeline, as the Cautious side proposed, and commit to a fully-funded, gated qualification 90 days after PVT entry, using real volume data from the production run. That ensures we still capture the $0.50 eventually, just not at the expense of the launch.

### Why This Works

- **Growth gets its momentum:** We don’t park the $0.50. We start the scoping work immediately so the option is ready the moment we have the data to de-risk it. If DVT exits cleanly, we’re positioned to lock in the savings before the BOM is frozen, avoiding a later running change.
- **Cautious gets its gates:** No unfunded work. No qualification starts without a PO. No change enters the BOM without a clean DVT exit and a fully passed reliability gate. The critical path is protected because the qualification is both parallel and gated.
- **The hard constraint is met:** The flex cable is electrically equivalent and doesn’t touch the data path; there’s no throughput or latency impact. The validation gates (**03-quality-reliability**’s bake, cycle testing, fleet validation) are designed specifically to catch any physical reliability issue that could affect uptime, which is exactly what our ICP demands per the Brain’s strategy doc: “>99.5% fleet uptime.”

### The Ask

Authorize the scoping PO now, with the explicit understanding that full qualification spending is gated on a clean DVT exit and an approved budget line from **06-finance**. This turns a binary “yes/no” fight into a staged, fact-based decision that protects both the 42% margin on the AMG-100 and our DVT schedule.